- Conditions
- Advanced, Persistent, or Recurrent Endometrial Cancer
- Interventions
- Everolimus, Tamoxifen, Letrozole, Medroxyprogesterone Acetate
- Drug
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 26
- States / cities
- Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 291
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Neoplasms, Tamoxifen
- Interventions
- Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
- Other
- Lead sponsor
- Medco Health Solutions, Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Franklin Lakes, New Jersey
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Interventions
- Switch, Guideline Directed Intervention (GDI)
- Drug · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-Dependent
- Interventions
- Atamestane, toremifene, letrozole
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 6
- States / cities
- Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms
- Interventions
- conjugated estrogens, medroxyprogesterone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 237
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
- Conditions
- X Linked Myotubular Myopathy
- Interventions
- ApoTamox 10mg, Placebo
- Drug
- Lead sponsor
- James Dowling
- Other
- Eligibility
- 6 Months and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rockville, Maryland
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Pembrolizumab, Tamoxifen, Vorinostat
- Biological · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Burbank, California • Corona, California + 17 more
- Conditions
- Breast Carcinoma
- Interventions
- Tamoxifen, Fulvestrant
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
- Interventions
- Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Menopause
- Interventions
- Personalized risk assessment, genetic counseling intervention
- Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Breast Cancer
- Interventions
- Fenretinide, Tamoxifen Citrate, Placebo
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Vasomotor Symptoms (VMS)
- Interventions
- Q-122, Placebo
- Drug
- Lead sponsor
- Que Oncology
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Breast Cancer
- Interventions
- Sample collection, Patient-reported outcomes
- Other · Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Carcinoma
- Interventions
- Biospecimen Collection, Electronic Health Record Review
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 290 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- diindolylmethane, placebo
- Dietary Supplement
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 521
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
- Conditions
- Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- Oana Danciu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
- Conditions
- Breast Cancer, Lymphoma, Hodgkin's Lymphoma
- Interventions
- surveys, Blood draw, Transvaginal ultrasounds
- Behavioral · Other · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 25 Years to 45 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2006
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- High Risk for Invasive Breast Cancer
- Interventions
- Tamoxifen, Tamoxifen (Nolvadex)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Jacksonville, Florida